Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of benzamide derivative to preparing antitumor drug

An anti-tumor drug, benzamide technology, applied in the chemical industry, can solve problems such as adverse reactions of anti-tumor drugs, and achieve the effects of not easy drug resistance, obvious effect, and obvious tumor inhibition effect.

Inactive Publication Date: 2010-12-22
FUDAN UNIV
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] Malignant tumors have become one of the most important causes of human death, but currently available anti-tumor drugs have various adverse reactions. Therefore, finding new anti-tumor drugs with low side effects has become a hot spot in the field of biomedicine

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of benzamide derivative to preparing antitumor drug

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0027] Example 1 Virtual screening of CypJ small molecule inhibitors

[0028] In the PDB protein structure database, the X-ray diffraction crystal structure of human CYPA protein was retrieved (PDB code: 1CWA). This structure is a complex crystal structure of CYPA and its natural inhibitor cyclosporin A (CsA). From this structure, the active site of CYPA was determined, and several key amino acid sites in the active site that can be inhibited by CsA were determined. Based on the highly homologous sequence of CYPJ and CYPA, we cooperated with the Shanghai Institute of Materia Medica, Chinese Academy of Sciences to establish a 3D structure model, which was also confirmed during subsequent protein crystallization and structural analysis (CYPJ PDB code: 1XYH). For the active site of CypJ, several small molecule databases were screened. The small molecule databases used for screening mainly include SPECS and CNPD. Finally, FD4 of the present invention was selected. The whole calcu...

Embodiment 2

[0029] Example 2 Using BIAcore molecular interaction instrument to verify virtual screening results

[0030] The BIAcore molecular interaction instrument is based on surface plasmon resonance technology to track the interaction between biomolecules, without any markers, so the authenticity of the experimental results is guaranteed to the greatest extent. In the experiment, the target biomolecule (CypJ protein) is fixed on the surface of the sensor chip, and then the small molecule compound is dissolved in the solvent and flows over the surface of the chip. The monitor can track the changes in the whole process of binding and dissociating the molecules in the detection solution to the target biomolecules on the chip surface in real time. According to the binding data of BIAcore, the N-[3-(benzamide)-5-(4-oxo-4H-3,1-benzoxazin-2-yl)phenyl]benzamide of the present invention and CypJ binding equilibrium-dissociation constant KD(M): 1.17×10 -5 .

Embodiment 3

[0031] Example 3 Using enzyme activity experiments to prove the ability of small molecule compounds to inhibit CypJ enzyme activity

[0032] There are many methods to determine CyP activity, but the α-chymotrypsin-coupled enzymic assay is the most commonly used. The principle is that oligopeptide substrates containing proline, such as N-succinyl-Ala-Ala-Pro-Phe (N-Succinyl-Ala-Ala-Pro-Phep-nitroanilide) in the solution CyP can catalyze the cis-trans isomerization of the substrate, that is, catalyze the proline from cis to trans; when it is in the trans structure, the C-terminal p-nitroanilide is α- The chymotrypsin cleaves to release the pigment group p-nitroaniline. The PPIase activity of CyP can be obtained by continuously measuring the change in absorbance at 390nm.

[0033] We used the reaction without adding small molecule inhibitors as a control reaction to determine the inhibitory rate of the small molecule ligand on the enzyme activity at different concentrations, and then...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the gene engineering and chemical field and relates to application of FD4: N-(3-(benzamide)-5-(4-oxo-4H-3,1-benzoxazine-2-yl) phenyl) benzamide to preparing an antitumor drug. The FD4 can obviously inhibit proliferation of tumor cells, is a drug designed aiming to a cell target CYPJ (Cyclophilin J), is not easy to cause the drug resistance and also has special and obvious effect to the tumor cells of a high expression CYPJ protein. Therefore, a small molecular compound is developed as a novel antitumor drug and has obvious tumor killing effect and good specificity, and the FD4 can be developed as the novel antitumor drug and provides a new way and means to treat and cure the tumor.

Description

Technical field [0001] The present invention relates to the field of chemical industry and medicine, and relates to N-[3-(benzamide)-5-(4-oxo-4H-3,1-benzoxazin-2-yl)phenyl]benzamide Application in the preparation of anti-tumor drugs. Background technique [0002] Cycliphilins (CyPs) are ubiquitously distributed intracellular proteins that exist in plants, bacteria and mammals. They are highly conserved and were originally discovered as cell receptors for cyclosporin A. Cyclosporin A (Cyclosporin A, CsA) is a cyclic peptide containing 11 amino acids isolated from fungal metabolites. It is an immunosuppressant used in organ transplantation and autoimmune diseases. It has been widely used in clinical practice. , With annual sales of more than US$5 billion. Since CsA has been used in clinical practice, it has shown various toxic and side effects, and its impact on the survival rate of patients and grafts has attracted more and more attention. Many scientific researchers are trying ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/536A61P35/00A61P1/16A61P1/00A61K9/00A61K9/20
Inventor 余龙张明君陈帅
Owner FUDAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com